Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Epigenetics and DNA Methylation, Cancer-related gene regulation, Breast Cancer Treatment Studies, and Wnt/β-catenin signaling in development and cancer.
Macrophage ALDH2 drives immunotherapy resistance by silencing CXCL9 through metabolic-epigenetic crosstalk.
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.
Assembly of an actinide-uranium single atom catalyst on defective MXenes for efficient NO electroreduction
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial
AEBP1 drives fibroblast-mediated T cell dysfunction in tumors.
Optimal Timing for Corticosteroid Therapy in Idiopathic Granulomatous Mastitis: A Retrospective Analysis Highlighting Early Intervention Efficacy.
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1
CACA Guidelines for Holistic Integrative Management of Breast Cancer
Breast cancer prognostic signature associated with DNA damage response-related genes
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1
Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer.
Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study.
BTNL9 is frequently downregulated and inhibits proliferation and metastasis via the P53/CDC25C and P53/GADD45 pathways in breast cancer
[A comparative study of breast cancer mass screening and opportunistic screening in Chinese women].
Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation.
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study.
Circular RNA 0001073 Attenuates Malignant Biological Behaviours in Breast Cancer Cell and Is Delivered by Nanoparticles to Inhibit Mice Tumour Growth.
The tumor suppressor Zinc finger protein 471 suppresses breast cancer growth and metastasis through inhibiting AKT and Wnt/β-catenin signaling.
Immunoglobulin superfamily member 10 is a novel prognostic biomarker for breast cancer.
Abstract GS1-08: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial
<p>Long noncoding RNA LINC01089 predicts clinical prognosis and inhibits cell proliferation and invasion through the Wnt/β-catenin signaling pathway in breast cancer</p>
Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.
Restoration of GATA4 expression impedes breast cancer progression by transcriptional repression of ReLA and inhibition of NF-κB signaling.
Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG).
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer.